Aberdeen Group plc Raises Position in Caribou Biosciences, Inc. $CRBU

Key Points

• Aberdeen Group plc increased its holdings in Caribou Biosciences by 126.5%, acquiring an additional 229,657 shares in the first quarter, bringing its total ownership to 411,144 shares valued at $375,000.
• Wall Street analysts have mixed ratings for Caribou Biosciences, with three giving it a Buy rating and a consensus target price of $6.67, while a recent report downgraded it to a sell.
• Caribou Biosciences reported a revenue of $2.67 million last quarter, exceeding expectations, and plans to post -1.64 earnings per share for the current year.

Aberdeen Group plc increased its holdings in Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) by 126.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 411,144 shares of the company's stock after acquiring an additional 229,657 shares during the period. Aberdeen Group plc owned about 0.44% of Caribou Biosciences worth $375,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the business. Jacobs Levy Equity Management Inc. purchased a new position in Caribou Biosciences in the fourth quarter valued at approximately $1,921,000. Cambridge Investment Research Advisors Inc. purchased a new position in Caribou Biosciences in the first quarter valued at approximately $559,000. Schonfeld Strategic Advisors LLC lifted its stake in Caribou Biosciences by 28.4% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 2,113,272 shares of the company's stock valued at $3,360,000 after purchasing an additional 467,738 shares during the last quarter. Two Sigma Advisers LP lifted its stake in Caribou Biosciences by 39.5% in the fourth quarter. Two Sigma Advisers LP now owns 1,470,700 shares of the company's stock valued at $2,338,000 after purchasing an additional 416,600 shares during the last quarter. Finally, Ameriprise Financial Inc. purchased a new position in Caribou Biosciences in the fourth quarter valued at approximately $649,000. 77.51% of the stock is owned by institutional investors.

Caribou Biosciences Price Performance

Shares of NASDAQ:CRBU traded down $0.05 during trading on Wednesday, hitting $1.96. 1,142,517 shares of the company were exchanged, compared to its average volume of 1,329,266. The company has a market cap of $182.05 million, a PE ratio of -1.10 and a beta of 2.55. The stock has a 50 day moving average of $1.76 and a 200 day moving average of $1.27. Caribou Biosciences, Inc. has a 52-week low of $0.66 and a 52-week high of $3.00.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.05. The firm had revenue of $2.67 million for the quarter, compared to the consensus estimate of $1.64 million. Caribou Biosciences had a negative return on equity of 62.35% and a negative net margin of 1,800.93%. Sell-side analysts forecast that Caribou Biosciences, Inc. will post -1.64 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded Caribou Biosciences from a "sell" rating to a "hold" rating in a research note on Sunday. Three analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $6.67.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.